Analysis of antimicrobial activity mechanisms of violacein against Staphylococcus aureus

Author(s)

Bruna de Araujo Lima

• Document type: Doctoral Thesis
• Institution: Universidade Estadual de Campinas (UNICAMP). Instituto de Biologia
• Defense date: 2013-00-00

Examining board members

Angélica Zaninelli Schreiber; Renata de Oliveira Mattos Graner; Luiz Alberto Beraldo de Moraes; John Anthony McCulloch

• Advisor: Marcelo Brocchi

Abstract

Violacein is a violet pigment produced by some bacterial species of environmental source, such as Chromobacterium violaceum and Janthinobacterium lividum. This molecule has numerous biological properties including antibacterial, antifungal, antiviral, antiprotozoal and antitumor activity, although the exact role in the physiology of producing microorganisms is still unknown. In this study, the antimicrobial activity of violacein produced commercially, semi purified extract and silver vanadate nanoparticles were evaluated against several species of gram-positive and gram-negative bacteria. Violacein exhibited antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), microorganisms that are often related to hospital-acquired infections. MIC (minimum inhibitory concentration) and MBC (minimum bactericidal concentration) values of violacein produced commercially were 1.25 ?M mM and 0.625 ?M respectively, and analysis of growth and time-kill curves showed an antibacterial effect against MRSA for 12 hours. The transmission electron microscopy showed the effects of violacein with morphological and ultra-structural changes, including changes in cell wall formation and abnormal division septum. The results obtained from the analysis of proteomic and transcriptomic revealed that violacein affects the expression of several functional classes of proteins and genes in MRSA, including biological processes in cell wall biosynthesis and cell division, supporting ultra-structural changes. In conclusion, violacein produced commercially demonstrated antimicrobial activity against S. aureus MRSA and the effects on the metabolism of S. aureus have been described, indicating possible targets and pathways affected by this drug. These data indicate violacein as a potential drug for the treatment of infections caused by MRSA (AU)